The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| THMO | -80% | N/A | N/A | -100% |
| S&P | +13.19% | +87.83% | +13.42% | +1,532% |
ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, CAR-Txpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
The company's switch to a contract development and manufacturing organization is taking shape.
Consider these biotech stocks to make your portfolio sizzle this summer.
| Q1 2024 | YOY Change | |
|---|---|---|
| Revenue | $2.74M | 0.0% |
| Gross Profit | $1.20M | 0.0% |
| Gross Margin | 43.92% | 0.0% |
| Employees | 25 | 0.0% |
| Net Income | -$2.00M | 0.0% |
| EBITDA | -$0.22M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2024 | YOY Change | |
|---|---|---|
| Net Cash | $1.18M | 0.0% |
| Accounts Receivable | $1.15M | 0.0% |
| Inventory | 1.2 | 0.0% |
| Q1 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.72M | 0.0% |
| Short Term Debt | $4.85M | 0.0% |
| Q1 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -98.83% | 0.0% |
| Q1 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.53M | 0.0% |
| Operating Free Cash Flow | -$0.51M | 0.0% |
| Metric | Q4 2023 | Q1 2024 | YoY Change |
|---|---|---|---|
| Price to Sales | 0.23 | 0.30 | - |
| Enterprise Value to EBITDA | -4.99 | -32.30 | - |
| Return on Equity | -1367.4% | -417.9% | - |
| Total Debt | $11.28M | $7.57M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
